Cargando…

Human Leukocyte Antigen Genes and Interferon Beta Preparations Influence Risk of Developing Neutralizing Anti-Drug Antibodies in Multiple Sclerosis

A significant proportion of patients with multiple sclerosis who receive interferon beta (IFNβ) therapy develop neutralizing antibodies (NAbs) that reduce drug efficacy. To investigate if HLA class I and II alleles are associated with development of NAbs against IFNβ we analyzed whether NAb status a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Link, Jenny, Lundkvist Ryner, Malin, Fink, Katharina, Hermanrud, Christina, Lima, Izaura, Brynedal, Boel, Kockum, Ingrid, Hillert, Jan, Fogdell-Hahn, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946519/ https://www.ncbi.nlm.nih.gov/pubmed/24608124 http://dx.doi.org/10.1371/journal.pone.0090479

Ejemplares similares

Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS
por: Andlauer, Till F. M., et al.
Publicado: (2020)

Importance of Human Leukocyte Antigen (HLA) Class I and II Alleles on the Risk of Multiple Sclerosis
por: Link, Jenny, et al.
Publicado: (2012)

Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon Beta
por: Ingenhoven, Kathleen, et al.
Publicado: (2017)

Long-Term Consequences of High Titer Neutralizing Antibodies to Interferon-β in Multiple Sclerosis
por: Dunn, Nicky, et al.
Publicado: (2020)

Serum IgG levels to Epstein-Barr and measles viruses in patients with multiple sclerosis during natalizumab and interferon beta treatment
por: Persson Berg, Linn, et al.
Publicado: (2022)

HLA-A Confers an HLA-DRB1 Independent Influence on the Risk of Multiple Sclerosis
por: Brynedal, Boel, et al.
Publicado: (2007)

Drug Tolerant Anti-drug Antibody Assay for Infliximab Treatment in Clinical Practice Identifies Positive Cases Earlier
por: Kharlamova, Nastya, et al.
Publicado: (2020)

Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis
por: Bachelet, Delphine, et al.
Publicado: (2016)

JC Polyomavirus Infection Is Strongly Controlled by Human Leucocyte Antigen Class II Variants
por: Sundqvist, Emilie, et al.
Publicado: (2014)

Deficient Phosphorylation of Stat1 in Leukocytes Identifies Neutralizing Antibodies in Multiple Sclerosis Patients Treated with Interferon-Beta
por: Gavasso, Sonia, et al.
Publicado: (2014)

Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results
por: Link, Jenny, et al.
Publicado: (2017)

Multiple Sclerosis Patients with Markedly Low Intrathecal Antibody Response in Sri Lanka
por: Gamage, S. M. K., et al.
Publicado: (2018)

First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis
por: Faustini, Francesca, et al.
Publicado: (2021)

Neutralizing Antibodies Against Interferon-Beta in Korean Patients with Multiple Sclerosis
por: Hyun, Jae-Won, et al.
Publicado: (2018)

Different HLA-DRB1 allele distributions in distinct clinical subgroups of sarcoidosis patients
por: Grunewald, Johan, et al.
Publicado: (2010)

Increased Serological Response Against Human Herpesvirus 6A Is Associated With Risk for Multiple Sclerosis
por: Engdahl, Elin, et al.
Publicado: (2019)

Changes to anti-JCV antibody levels in a Swedish national MS cohort
por: Warnke, Clemens, et al.
Publicado: (2013)

Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosis
por: Manceau, Philippe, et al.
Publicado: (2014)

Beta-interferons in multiple sclerosis
por: Aggarwal, Sourabh, et al.
Publicado: (2010)

Low sun exposure increases multiple sclerosis risk both directly and indirectly
por: Hedström, Anna Karin, et al.
Publicado: (2019)

Interaction between adolescent obesity and HLA risk genes in the etiology of multiple sclerosis
por: Hedström, Anna Karin, et al.
Publicado: (2014)

Smoking Attributable Risk in Multiple Sclerosis
por: Manouchehrinia, Ali, et al.
Publicado: (2022)

Interaction between passive smoking and two HLA genes with regard to multiple sclerosis risk
por: Hedström, Anna Karin, et al.
Publicado: (2014)

The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy
por: Paolicelli, Damiano, et al.
Publicado: (2016)

LEUKOCYTES AND INTERFERON IN THE HOST RESPONSE TO VIRAL INFECTIONS : I. MOUSE LEUKOCYTES AND LEUKOCYTE-PRODUCED INTERFERON IN VACCINIA VIRUS INFECTION IN VITRO
por: Glasgow, Lowell A.
Publicado: (1965)

Stressful life events are associated with the risk of multiple sclerosis
por: Jiang, X., et al.
Publicado: (2020)

The familial risk and heritability of multiple sclerosis and its onset phenotypes: A case–control study
por: Boles, Graysen Steele, et al.
Publicado: (2023)

The role of herpesvirus 6A and 6B in multiple sclerosis and epilepsy
por: Dunn, Nicky, et al.
Publicado: (2020)

The association between exposure to interferon-beta during pregnancy and birth measurements in offspring of women with multiple sclerosis
por: Burkill, Sarah, et al.
Publicado: (2019)

Association between exposure to combustion-related air pollution and multiple sclerosis risk
por: Hedström, Anna Karin, et al.
Publicado: (2023)

Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry
por: Hellwig, Kerstin, et al.
Publicado: (2020)

‘Beta-interferons’ and ‘oligoclonal bands’ in multiple sclerosis in India
por: Hassan, K. M.
Publicado: (2011)

Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis
por: Creeke, Paul I., et al.
Publicado: (2013)

Spasticity treatment patterns among people with multiple sclerosis: a Swedish cohort study
por: Smith, Kelsi A, et al.
Publicado: (2023)

INTERFERON PRODUCTION BY MOUSE LEUKOCYTES IN VITRO AND IN VIVO
por: Glasgow, Lowell A., et al.
Publicado: (1963)

Interferons as cytokines regulating leukocyte functions in vivo
por: Virelizier, J.-L.
Publicado: (1985)

Understanding interactions between risk factors, and assessing the utility of the additive and multiplicative models through simulations
por: Diaz-Gallo, Lina-Marcela, et al.
Publicado: (2021)

Enrichment of coronavirus-induced interferon-producing blood leukocytes increases the interferon yield per cell: A study with pig leukocytes
por: Nowacki, W., et al.
Publicado: (1993)

Neutralizing antibodies explain the poor clinical response to Interferon beta in a small proportion of patients with Multiple Sclerosis: a retrospective study
por: Sbardella, Emilia, et al.
Publicado: (2009)

Mendelian randomization shows a causal effect of low vitamin D on multiple sclerosis risk
por: Rhead, Brooke, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_jc7n0cg7c3q8l160bd7n1mic2s